under Ranbaxy

Indian business groups are learning to separate emotion from valuation. For shareholders, this can only be a good sign.

0

15 Apr 2010 | BY Sourav Majumdar

Suddenly, the Indian pharma gameplan appears more like irrational overreach and less like an achievement

0

26 Jun 2009 | BY Ninad D. Sheth
Syndicate content